Summary
Regenerative medicine refers to the use of the theoretical methods of biology and engineering to create the structure and function of normal tissues and organs for lost or damaged tissues and organs. In recent years, regenerative medicine, as an emerging frontier medical field, has developed rapidly.
This report is an analysis report of the regenerative medicine industry. It mainly analyzes the interdisciplinary technologies and disciplines in the field of regenerative medicine and its value in clinical applications. At present, regenerative medicine has brought new challenges to most medical problems faced by human beings. hope.
The American Regenerative Medicine Industry Alliance has selected multiple indications (such as sickle cell disease, hemophilia A, multiple myeloma, etc.) as sample analysis with reference to ten years of data from the Congressional Budget Office. Treatment can bring long-term benefits to the clinical treatment of these rare blood diseases, and the overall medical cost may be saved by 18-30%.
The regenerative medicine industry is still in the early stage of development at home and abroad, and it is expected that the market will continue to expand in the future
As a cutting-edge medical field with cross-application of science and technology, regenerative medicine is currently in the initial stage of development at home and abroad, and small molecule & macromolecule drugs still occupy an indispensable position in the segmented field. The global and Chinese regenerative medicine field will maintain a growth trend in the next few years. It is estimated that the global regenerative medicine market will reach 131.1 billion US dollars in 2030, with a compound annual growth rate of 21%; China’s regenerative medicine market is expected to reach 92.66 billion yuan in 2030. .
The industrial chain of the regenerative medicine industry is relatively complete, and has been favored by the capital market in recent years
At this stage, my country’s regenerative medicine industry is favored by many capital market investment institutions, and has been paid attention to by investors in the fields of small molecule and macromolecular drugs, gene technology, tissue engineering, cell technology, services and equipment. In the regenerative medicine industry chain, the upstream of upstream regenerative medicine provides equipment, services and raw materials corresponding to the four technologies in the midstream; the R&D and manufacturing of the midstream are mainly used in the fields of medical anti-aging, anti-cancer and anti-cancer in the downstream.
There are differences in policy for different fields of regenerative medicine, which are constantly favorable and stricter regulation.
Policy drivers have played a role in regenerative medicine, high-value consumables, 3D printing manufacturing and other fields; among them, the accelerated development of cell therapy, bone tissue, muscle system and cardiovascular system related industries is particularly mentioned. In the relevant regulatory policies, policies related to strengthening cell supervision and management have been mentioned many times. In 2015, the “Stem Cell Clinical Research Management Method” was issued to clarify that stem cell therapy technology is no longer managed in accordance with the third type of medical technology. Since then, the supervision has gradually become stricter.
To view the full report click here
Note: Unless it is marked as original, it is all submitted by netizens or institutions for sharing. If you have any needs for publicity, please contact [email protected].
This article is reprinted from: https://www.dx2025.com/archives/19992.html
This site is for inclusion only, and the copyright belongs to the original author.